Biohaven Pharmaceutical Holding Revenue 2016-2022 | BHVN

Biohaven Pharmaceutical Holding revenue from 2016 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Biohaven Pharmaceutical Holding Annual Revenue
(Millions of US $)
2021 $463
2020 $64
2019 $
2018 $
2017 $
2016 $
2015 $
Biohaven Pharmaceutical Holding Quarterly Revenue
(Millions of US $)
2022-06-30 $215
2022-03-31 $319
2021-12-31 $190
2021-09-30 $136
2021-06-30 $93
2021-03-31 $44
2020-12-31 $35
2020-09-30 $18
2020-06-30 $10
2020-03-31 $1
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.052B 9.22
GSK (GSK) United Kingdom $62.454B 7.50
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.939B 16.64
Ginkgo Bioworks Holdings (DNA) United States $6.283B 0.00
Myovant Sciences (MYOV) United Kingdom $2.444B 0.00
Arcus Biosciences (RCUS) United States $1.941B 37.89
Emergent Biosolutions (EBS) United States $1.068B 6.19
ADC Therapeutics SA (ADCT) Switzerland $0.402B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.083B 0.00
SQZ Biotechnologies (SQZ) United States $0.073B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00